{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968870",
  "id": "02968870",
  "pages": 6,
  "price_sensitive": true,
  "date": "20250714",
  "time": "0834",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrqtxw4h73d0.pdf",
  "summary": "- **Clinical Trial Update (Phase 1b azer-cel CAR T therapy)**  \n  - **75% Overall Response Rate (ORR)**: 6 Complete Responses (CR) and 3 Partial Responses (PR) in relapsed DLBCL patients.  \n  - **Durability**: First patient remains cancer-free at 15+ months; others show durable responses at 2, 5, and 11+ months.  \n  - **High-Unmet-Need Population**: Patients had failed 3\u20136 prior therapies, including autologous CAR-T.  \n  - **Regulatory Milestone**: FDA Fast Track Designation secured; Type B (End of Phase 1) meeting planned for Q4 2025 to discuss pivotal trial design.  \n  - **Trial Expansion**: Now enrolling CAR T-na\u00efve patients with other lymphomas (PCNSL, CLL/SLL, MZL, WM, FL).  \n\n*No capital markets or liquidity-impacting actions announced.*",
  "usage": {
    "prompt_tokens": 2759,
    "completion_tokens": 206,
    "total_tokens": 2965,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-13T22:55:29.597239"
}